Showing 2311-2320 of 5909 results for "".
- Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNIhttps://modernod.com/news/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-aqueous-outflow-restorative-procedure-with-omni/2482226/Sight Sciences announced the results as published in the American Journal of Ophthalmology (AJO) International of a large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery (MIGS) technologies.
- Lenz Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trialshttps://modernod.com/news/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials/2482207/Lenz Therapeutics announced positive topline results from its phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. In phase 3 safety and efficacy trials (CLARITY 1 and 2), our lead product candidate LNZ100 (1.75% ac
- Melt Pharmaceuticals Completes Stock Refinancing to Support Further Development of MELT-300https://modernod.com/news/melt-pharmaceuticals-completes-stock-refinancing-to-support-further-development-of-melt-300/2482198/Melt Pharmaceuticals announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors. The capital raised will primarily support the further development of MELT-300, including the MELT-300 phase 3 program. MELT-300, a n
- SpyGlass Pharma Unveils 1-Year Data of Its Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucomahttps://modernod.com/news/spyglass-pharma-unveils-1-year-data-of-its-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-eyes-with-glaucoma/2482196/SpyGlass Pharma announced 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ IOL-based drug delivery platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation
- OnPoint Vision Initiates Phase 1 Trial of AccuraSee Intraocular Pseudophakic Capsular Lens Magnifierhttps://modernod.com/news/onpoint-vision-initiates-phase-1-trial-of-accurasee-intraocular-pseudophakic-capsular-lens-magnifier/2482184/OnPoint Vision announced open enrollment of the phase 1 IDE clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with a pre-existing 6mm acrylic posterior chamber IOL. The IOPCL MAG is neu
- Staar Surgical Celebrates Three Million Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-celebrates-three-million-implantable-collamer-lenses/2482170/Staar Surgical announced that more than 3 million Implantable Collamer Lens (ICLs) have been sold globally.[1] “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction
- Neurolens Restructures Leadership Teamhttps://modernod.com/news/neurolens-restructures-leadership-team/2482165/Neurolens announced a strategic leadership restructure, which includes Davis Corley, co-founder, returning as CEO. Other leadership hires: Gregory Boisse, SVP of Operations Nathan Schomas, SVP of Digital Innovation
- Survey: Communications Adjustments Could Supercharge Contact Lens Adoptionhttps://modernod.com/news/survey-communications-adjustments-could-supercharge-contact-lens-adoption/2482164/Simple adjustments to how eye care practices communicate with patients may attract a significantly higher number of contact lens wearers, according to new data from the Contact Lens Institute (CLI). The industry association is previewing its latest
- Richard Lindstrom, MD, to Lead Eye Care Biopharmaceutical Company Surface Ophthalmicshttps://modernod.com/news/richard-lindstrom-md-to-lead-new-eye-care-biopharmaceutical-company-surface-ophthalmics/2482161/Surface Ophthalmics announced the appointment of Richard Lindstrom, MD, as Founder and Chairman. Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, PA. Dr. Lindstrom will lead in partnership with Surface’s Board of Directors, including
- MediPrint Ophthalmics Completes Phase 2b Study of Drug-Eluting Contact Lens for Glaucomahttps://modernod.com/news/mediprint-ophthalmics-completion-phase-2b-study-of-drug-eluting-contact-lens-for-glaucoma/2482158/MediPrint Ophthalmics announced it has completed its SIGHT-2 phase 2b study evaluating its lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens leveraging com